Summary
45 / 100 · Bulios Score
What speaks for it
- It bought back its own shares for 939.6M € in the last fiscal year, 6.9% of its market value.
- It has been profitable 6 years in a row.
What to watch
- Earnings per share fell by 6.1% a year over the last 3 years.
- It missed profit estimates 6 times in the last 8 quarters.
- You pay 28.7 EUR for 1 EUR of yearly profit, a lot for its sector.
- It earns only 6.2 EUR a year on every 100 EUR of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedPrice against the Bulios Fair Price
P/E against the industry (Medical - Diagnostics & Research)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 28.7 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 6.0% a year over 5 years. Over the last 3 years it grew by 2.8% a year. For the next fiscal year analysts expect revenue to fall by 1.7%. Earnings per share fell by 6.1% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.96%
- Paid out of profit
- 27%
- Raised in a row
- 1 year
You receive $0.84 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 1
- Sell 1
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.